Our top pick for
Belden Inc is an electrical equipment & parts business based in the US. Belden shares (BDC) are listed on the NYSE and all prices are listed in US Dollars. Belden employs 6,200 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$60.31|
|52-week range||$30.02 - $62.95|
|50-day moving average||$58.93|
|200-day moving average||$52.33|
|Wall St. target price||$67.17|
|Dividend yield||$0.2 (0.33%)|
|Earnings per share (TTM)||$2.14|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-2.24%|
|1 month (2021-09-24)||2.38%|
|3 months (2021-07-23)||26.20%|
|6 months (2021-04-23)||37.47%|
|1 year (2020-10-23)||74.11%|
|2 years (2019-10-24)||10.20%|
|3 years (2018-10-24)||5.92%|
|5 years (2016-10-24)||69.13|
Valuing Belden stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Belden's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Belden's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, Belden shares trade at around 28x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Belden's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.14. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Belden's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Belden's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $308.4 million.
The EBITDA is a measure of a Belden's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2.1 billion|
|Operating margin TTM||10.05%|
|Gross profit TTM||$664.1 million|
|Return on assets TTM||4.12%|
|Return on equity TTM||12.8%|
|Market capitalisation||$2.7 billion|
TTM: trailing 12 months
There are currently 1.7 million Belden shares held short by investors – that's known as Belden's "short interest". This figure is 15.2% up from 1.5 million last month.
There are a few different ways that this level of interest in shorting Belden shares can be evaluated.
Belden's "short interest ratio" (SIR) is the quantity of Belden shares currently shorted divided by the average quantity of Belden shares traded daily (recently around 266624.96050553). Belden's SIR currently stands at 6.33. In other words for every 100,000 Belden shares traded daily on the market, roughly 6330 shares are currently held short.
However Belden's short interest can also be evaluated against the total number of Belden shares, or, against the total number of tradable Belden shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Belden's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Belden shares in existence, roughly 40 shares are currently held short) or 0.0429% of the tradable shares (for every 100,000 tradable Belden shares, roughly 43 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Belden.
Find out more about how you can short Belden stock.
Dividend payout ratio: 5.31% of net profits
Recently Belden has paid out, on average, around 5.31% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.33% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Belden shareholders could enjoy a 0.33% return on their shares, in the form of dividend payments. In Belden's case, that would currently equate to about $0.2 per share.
While Belden's payout ratio might seem low, this can signify that Belden is investing more in its future growth.
Belden's most recent dividend payout was on 5 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 13 September 2021 (the "ex-dividend date").
Belden's shares were split on a 1:2 basis on 15 July 2004. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Belden shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Belden shares which in turn could have impacted Belden's share price.
Over the last 12 months, Belden's shares have ranged in value from as little as $30.0152 up to $62.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Belden's is 1.4048. This would suggest that Belden's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Belden Inc. operates as a signal transmission solutions company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. It operates in two segments, Enterprise Solutions and Industrial Solutions. The Enterprise Solutions segment offers copper cable and connectivity solutions, fiber cable and connectivity solutions, racks and enclosures, and signal extension and matrix switching systems for use in applications, such as local area networks, data centers, access control, fiber, and home and building automation. It also provides power, cooling, and airflow management products for mission-critical data center operations; and end-to-end copper and fiber network systems, which include cable, assemblies, interconnect panels, and enclosures. This segment serves customers in markets comprising healthcare, education, financial, government, and corporate enterprises, as well as end-markets, including sports venues and academia. The Industrial Solutions segment offers infrastructure components and on-machine connectivity systems; and industrial Ethernet switches, network management software, routers, firewalls, gateways, input/output (I/O) connectors/systems, industrial Ethernet cables, optical fiber industrial Ethernet cables, Fieldbus cables, IP and networking cables, I/O modules, distribution boxes, and customer specific wiring solutions.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.